OBJECTIVE: This was a phase II study of perillyl alcohol in the treatment of advanced ovarian cancer. The primary endpoint was to evaluate the 6-month progression-free rate of perillyl alcohol as compared with historic controls. Secondary objectives were to evaluate the objective response rate, time to progression and survival, dropout rate, and number of cycles administered; define the qualitative nature of acute and chronic toxicities; and evaluate the effect of perillyl alcohol on triglycerides and total, HDL, and LDL cholesterol levels. Methods. Women who had received prior platinum-based therapy and had residual or recurrent disease were eligible. Perillyl alcohol was administered orally, four times daily, at a dose of 1200 mg/m(2). This was repeated until disease progression or unacceptable toxicity was experienced. RESULTS: The 6-month progression-free rate was 17%. None of the patients achieved a complete or partial response. The median progression-free survival was 1.7 months. The median overall survival was 9.1 months. Compliance was greater than 90% but gastrointestinal toxicity (grade 1-2 nausea, satiety, eructation in 70%) and fatigue (grade 1-2 in 40%) were common and limited the ability to escalate the dose from 1200 to 1500 mg/m(2). CONCLUSION: Perillyl alcohol administered at this dose and formulation did not exhibit signs of extending the time-to-progression in patients with advanced ovarian carcinoma.
OBJECTIVE: This was a phase II study of perillyl alcohol in the treatment of advanced ovarian cancer. The primary endpoint was to evaluate the 6-month progression-free rate of perillyl alcohol as compared with historic controls. Secondary objectives were to evaluate the objective response rate, time to progression and survival, dropout rate, and number of cycles administered; define the qualitative nature of acute and chronic toxicities; and evaluate the effect of perillyl alcohol on triglycerides and total, HDL, and LDL cholesterol levels. Methods. Women who had received prior platinum-based therapy and had residual or recurrent disease were eligible. Perillyl alcohol was administered orally, four times daily, at a dose of 1200 mg/m(2). This was repeated until disease progression or unacceptable toxicity was experienced. RESULTS: The 6-month progression-free rate was 17%. None of the patients achieved a complete or partial response. The median progression-free survival was 1.7 months. The median overall survival was 9.1 months. Compliance was greater than 90% but gastrointestinal toxicity (grade 1-2 nausea, satiety, eructation in 70%) and fatigue (grade 1-2 in 40%) were common and limited the ability to escalate the dose from 1200 to 1500 mg/m(2). CONCLUSION:Perillyl alcohol administered at this dose and formulation did not exhibit signs of extending the time-to-progression in patients with advanced ovarian carcinoma.
Authors: Juliana de Saldanha da Gama Fischer; Paulo Costa Carvalho; Clovis Orlando da Fonseca; Lujian Liao; Wim M Degrave; Maria da Gloria da Costa Carvalho; John R Yates; Gilberto B Domont Journal: J Proteome Res Date: 2010-09-27 Impact factor: 4.466
Authors: Juliana de Saldanha da Gama Fischer; Lujian Liao; Paulo C Carvalho; Valmir C Barbosa; Gilberto B Domont; Maria da Gloria da Costa Carvalho; John R Yates Journal: J Proteomics Date: 2010-01-18 Impact factor: 4.044
Authors: Glenn Liu; Kurt Oettel; Howard Bailey; Lynn Van Ummersen; Kendra Tutsch; Mary Jane Staab; Dorothea Horvath; Dona Alberti; Rhoda Arzoomanian; Hamied Rezazadeh; James McGovern; Emily Robinson; David DeMets; George Wilding Journal: Invest New Drugs Date: 2003-08 Impact factor: 3.850
Authors: Sherry Morgan Meadows; Daniel Mulkerin; Jordan Berlin; Howard Bailey; Jill Kolesar; Deb Warren; James P Thomas Journal: Int J Gastrointest Cancer Date: 2002
Authors: Steven P Stratton; David S Alberts; Janine G Einspahr; Paul M Sagerman; James A Warneke; Clara Curiel-Lewandrowski; Paul B Myrdal; Kelly L Karlage; Brian J Nickoloff; Chris Brooks; Kathylynn Saboda; Michael L Yozwiak; Mary F Krutzsch; Chengcheng Hu; Maria Lluria-Prevatt; Zigang Dong; G Timothy Bowden; Peter H Bartels Journal: Cancer Prev Res (Phila) Date: 2010-01-26
Authors: Nitin S Nandurkar; Jianjun Zhang; Qing Ye; Larissa V Ponomareva; Qing-Bai She; Jon S Thorson Journal: J Med Chem Date: 2014-08-25 Impact factor: 7.446